The largest database of trusted experimental protocols

Alzet mini osmotic pumps model 2006

Manufactured by Durect
Sourced in United States

The Alzet Mini-osmotic Pumps (model 2006) are small, implantable devices designed for continuous and controlled delivery of substances in laboratory animals. They operate on the principle of osmosis to deliver the substances at a constant rate over an extended period of time.

Automatically generated - may contain errors

2 protocols using alzet mini osmotic pumps model 2006

1

Investigating Inflammatory Mechanisms in Atherosclerosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Synthetic human IMD1-53 was from Phoenix Pharmaceuticals (Burlingame, CA, USA). Alzet Mini-osmotic Pumps (model 2006) were from DURECT Corp (Cupertino, CA, USA). Primary antibodies for IMD (sc-86272), β-actin (sc-47778), IL-1β (sc-7884), and all horseradish peroxidase (HRP)-conjugated secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies for CD68 (ab125212), α-actin (ab5694), glucose-regulated protein78 (GRP78, ab21865), activating transcription factor (ATF4, ab216839), cleaved ATF6 (ab203119), p-inositol-requiring kinase 1 alpha (p-IRE1α, ab48187), CHOP (ab10444), cleaved-caspase-3 (ab13847) were from Abcam PLC (Cambridge, UK). Apoptosis-associated speck-like protein containing CARD (ASC, SAB4501315) were from Sigma-Aldrich (St. Louis, MO, USA). Dylight-labeled secondary antibodies were from EarthOx Life Sciences (Millbrae, CA, USA). The kit for reverse transcription of RNA and SuperReal PreMix Plus for real-time PCR (TIANGEN Biotech, Beijing, China). The oil red O and taurine (Tau) were from Sigma-Aldrich (St. Louis, MO, USA). Oxidized human LDL (ox-LDL, YB-002) was from Yiyuan Biotechnology (Guangzhou, China). Other chemicals and reagents were of analytical grade.
+ Open protocol
+ Expand
2

Evaluating PRI-724 Dosing Regimens

Check if the same lab product or an alternative is used in the 5 most similar protocols
PRI-724 (PRISM Pharma Co., Ltd.) was diluted in phosphate-buffered saline (PBS) and injected intraperitoneally once daily at a concentration of 5 or 20 mg/kg body weight for 6 weeks. For the 1 week ON/OFF experiment, the reagent (5 mg/kg/day) was administered intraperitoneally for 6 weeks during which animals were treated for a total of three cycles, each consisting of 1 week of once-daily dosing followed by 1 week without dosing. In a separate experiment, PRI-724 was administered intraperitoneally at 15 mg/kg body weight at a frequency of once or twice per week for 6 weeks. Alternatively, PRI-724 was dosed by subcutaneous infusion (1 mg/kg/day) for 6 weeks using implanted ALZET Mini-osmotic pumps MODEL 2006 (DURECT, Cupertino, CA). On the last day of the respective treatment, each animal was humanely killed and the liver was recovered at necropsy. Separate segments of each animal’s liver were fixed in formalin (for standard histology and immunohistochemistry); embedded in optimal cutting temperature (OCT) compound and frozen at −80 °C (for cryosectioning followed by immunohistochemistry); or flash-frozen in liquid nitrogen (for analysis of hydroxyproline content and assays of RNA and protein expression).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!